Abstract
Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; CD152), was approved by the Food and Drug Administration in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened treatment options, immune-related adverse events (irAEs) are associated with ipilimumab therapy, including dermatologic effects, colitis and diarrhea, endocrine effects, hepatotoxicity, ocular effects, renal effects, neurologic effects, and others. In this article, a critical evaluation of the underlying mechanisms of irAEs associated with anti-CTLA-4 therapy is presented. Additionally, potentially beneficial effects of combinational therapies to alleviate ipilimumab-induced irAEs in malignant melanoma are discussed. Future research is warranted to elucidate the efficacy of such combination therapies and specific biomarkers that would help to predict a clinical response to ipilimumab in patients with malignant melanoma.
| Original language | English |
|---|---|
| Pages (from-to) | 412-424 |
| Number of pages | 13 |
| Journal | Translational Research |
| Volume | 166 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 1 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
- Biochemistry, medical
- Public Health, Environmental and Occupational Health
Cite this
Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. / Quirk, Shannon K.; Shure, Anna K.; Agrawal, Devendra K.
In: Translational Research, Vol. 166, No. 5, 01.11.2015, p. 412-424.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma
AU - Quirk, Shannon K.
AU - Shure, Anna K.
AU - Agrawal, Devendra K.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; CD152), was approved by the Food and Drug Administration in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened treatment options, immune-related adverse events (irAEs) are associated with ipilimumab therapy, including dermatologic effects, colitis and diarrhea, endocrine effects, hepatotoxicity, ocular effects, renal effects, neurologic effects, and others. In this article, a critical evaluation of the underlying mechanisms of irAEs associated with anti-CTLA-4 therapy is presented. Additionally, potentially beneficial effects of combinational therapies to alleviate ipilimumab-induced irAEs in malignant melanoma are discussed. Future research is warranted to elucidate the efficacy of such combination therapies and specific biomarkers that would help to predict a clinical response to ipilimumab in patients with malignant melanoma.
AB - Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; CD152), was approved by the Food and Drug Administration in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened treatment options, immune-related adverse events (irAEs) are associated with ipilimumab therapy, including dermatologic effects, colitis and diarrhea, endocrine effects, hepatotoxicity, ocular effects, renal effects, neurologic effects, and others. In this article, a critical evaluation of the underlying mechanisms of irAEs associated with anti-CTLA-4 therapy is presented. Additionally, potentially beneficial effects of combinational therapies to alleviate ipilimumab-induced irAEs in malignant melanoma are discussed. Future research is warranted to elucidate the efficacy of such combination therapies and specific biomarkers that would help to predict a clinical response to ipilimumab in patients with malignant melanoma.
UR - http://www.scopus.com/inward/record.url?scp=84944281519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944281519&partnerID=8YFLogxK
U2 - 10.1016/j.trsl.2015.06.005
DO - 10.1016/j.trsl.2015.06.005
M3 - Review article
VL - 166
SP - 412
EP - 424
JO - Translational Research
JF - Translational Research
SN - 1931-5244
IS - 5
ER -